Patent · US Active

Antibodies targeting Fc receptor-like 5 and methods of use

US10913796B2 · kind B2 · utility

3Cited by

12References

44Claims

0Family size

Assignees

Memorial Sloan Kettering Cancer Center · US
Eureka Therapeutics, Inc. · US

Inventors

Renier J. Brentjens · New York, US
Eric Smith · New York, US
Cheng Liu · Richmond, US

Key dates

Filing date	Jun 4, 2018
Grant date	Feb 9, 2021
Priority date	—
Expiry date	Nov 25, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/622
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.